| Economics of bone marrow transplantation |
| KA Schulman |
|
JCO May 1 1996: 1409–1410.
[PDF]
|
 |
| CA-125: an evolving role in the management of ovarian cancer |
| M Markman |
|
JCO May 1 1996: 1411–1412.
[PDF]
|
|
|
Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy |
| |
R Barr, W Furlong, J Henwood, D Feeny, J Wegener, I Walker, and M Brain |
| |
JCO May 1 1996: 1413–1420.
[Abstract]
[PDF]
|
|
|
Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results |
| |
S Viviani, G Bonadonna, A Santoro, V Bonfante, M Zanini, L Devizzi, F Soncini, and P Valagussa |
| |
JCO May 1 1996: 1421–1430.
[Abstract]
[PDF]
|
|
|
Recovery of overall and local lung function loss 18 months after irradiation for malignant lymphoma |
| |
LJ Boersma, EM Damen, RW de Boer, SH Muller, RA Valdes Olmos, N van Zandwijk, and JV Lebesque |
| |
JCO May 1 1996: 1431–1441.
[Abstract]
[PDF]
|
|
|
Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology |
| |
R Sankila, S Garwicz, JH Olsen, H Dollner, H Hertz, A Kreuger, F Langmark, M Lanning, T Moller, and H Tulinius |
| |
JCO May 1 1996: 1442–1446.
[Abstract]
[PDF]
|
|
|
High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma |
| |
WI Bensinger, SD Rowley, T Demirer, K Lilleby, K Schiffman, RA Clift, FR Appelbaum, A Fefer, T Barnett, R Storb, T Chauncey, RT Maziarz, J Klarnet, P McSweeney, L Holmberg, DG Maloney, CH Weaver, and CD Buckner |
| |
JCO May 1 1996: 1447–1456.
[Abstract]
[PDF]
|
|
|
Psychologic and neuropsychologic impact of autologous bone marrow transplantation |
| |
TA Ahles, DM Tope, C Furstenberg, D Hann, and L Mills |
| |
JCO May 1 1996: 1457–1462.
[Abstract]
[PDF]
|
|
|
High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial |
| |
SM Stemmer, PJ Cagnoni, EJ Shpall, SI Bearman, S Matthes, C Dufton, T Day, S Taffs, L Hami, C Martinez, MH Purdy, J Arron, and RB Jones |
| |
JCO May 1 1996: 1463–1472.
[Abstract]
[PDF]
|
|
|
Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer |
| |
S Rodenhuis, A Westermann, MJ Holtkamp, WJ Nooijen, JW Baars, E van der Wall, IC Slaper-Cortenbach, and JH Schornagel |
| |
JCO May 1 1996: 1473–1483.
[Abstract]
[PDF]
|
|
|
Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients |
| |
JT Slattery, TF Kalhorn, GB McDonald, K Lambert, CD Buckner, WI Bensinger, C Anasetti, and FR Appelbaum |
| |
JCO May 1 1996: 1484–1494.
[Abstract]
[PDF]
|
|
|
Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors |
| |
SJ Clarke, J Hanwell, M de Boer, A Planting, J Verweij, M Walker, R Smith, AL Jackman, LR Hughes, KR Harrap, GT Kennealey, and IR Judson |
| |
JCO May 1 1996: 1495–1503.
[Abstract]
[PDF]
|
|
|
Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia |
| |
WL Furman, SD Baker, CB Pratt, GK Rivera, WE Evans, and CF Stewart |
| |
JCO May 1 1996: 1504–1511.
[Abstract]
[PDF]
|
|
|
Prognostic importance of p15INK4B and p16INK4 gene inactivation in childhood acute lymphocytic leukemia |
| |
M Heyman, O Rasool, L Borgonovo Brandter, Y Liu, D Grander, S Soderhall, G Gustavsson, and S Einhorn |
| |
JCO May 1 1996: 1512–1520.
[Abstract]
[PDF]
|
|
|
Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study |
| |
CP Steuber, J Krischer, T Holbrook, B Camitta, V Land, C Sexauer, D Mahoney, and H Weinstein |
| |
JCO May 1 1996: 1521–1525.
[Abstract]
[PDF]
|
|
|
Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy |
| |
BH Kushner, MP LaQuaglia, N Wollner, PA Meyers, KL Lindsley, F Ghavimi, TE Merchant, F Boulad, NK Cheung, MA Bonilla, G Crouch, JF Kelleher, Jr, PG Steinherz, and WL Gerald |
| |
JCO May 1 1996: 1526–1531.
[Abstract]
[PDF]
|
|
|
Results of a stage-based protocol for the treatment of retinoblastoma |
| |
E Schvartzman, G Chantada, A Fandino, MT de Davila, E Raslawski, and J Manzitti |
| |
JCO May 1 1996: 1532–1536.
[Abstract]
[PDF]
|
|
|
Resection of primary tumor at diagnosis in stage IV-S neuroblastoma: does it affect the clinical course? |
| |
M Guglielmi, B De Bernardi, A Rizzo, S Federici, C Boglino, F Siracusa, A Leggio, F Cozzi, G Cecchetto, L Musi, T Bardini, AM Fagnani, GC Bartoli, A Pampaloni, D Rogers, M Conte, C Milanaccio, and P Bruzzi |
| |
JCO May 1 1996: 1537–1544.
[Abstract]
[PDF]
|
|
|
Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 |
| |
GJ Rustin, AE Nelstrop, P McClean, MF Brady, WP McGuire, WJ Hoskins, H Mitchell, and HE Lambert |
| |
JCO May 1 1996: 1545–1551.
[Abstract]
[PDF]
|
|
|
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma |
| |
AP Kudelka, D Tresukosol, CL Edwards, RS Freedman, C Levenback, P Chantarawiroj, C Gonzalez de Leon, EE Kim, T Madden, B Wallin, M Hord, C Verschraegen, M Raber, and JJ Kavanagh |
| |
JCO May 1 1996: 1552–1557.
[Abstract]
[PDF]
|
|
|
Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave- Roussy Breast Cancer Group |
| |
R Arriagada, MG Le, F Rochard, and G Contesso |
| |
JCO May 1 1996: 1558–1564.
[Abstract]
[PDF]
|
|
|
Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life |
| |
SM Swain, J Rowland, K Weinfurt, C Berg, ME Lippman, L Walton, E Egan, D King, I Spertus, and SF Honig |
| |
JCO May 1 1996: 1565–1572.
[Abstract]
[PDF]
|
|
|
Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity |
| |
A Ribas, J Albanell, J Bellmunt, LA Sole-Calvo, B Bermejo, E Gallardo, R Vidal, R Vera, N Eres, J Carulla, and J Baselga |
| |
JCO May 1 1996: 1573–1580.
[Abstract]
[PDF]
|
|
|
Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients |
| |
M Sandstrom, A Freijs, R Larsson, P Nygren, ML Fjallskog, J Bergh, and MO Karlsson |
| |
JCO May 1 1996: 1581–1588.
[Abstract]
[PDF]
|
|
|
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study |
| |
M Perloff, L Norton, AH Korzun, WC Wood, RW Carey, A Gottlieb, JC Aust, A Bank, RT Silver, F Saleh, GP Canellos, MC Perry, RB Weiss, and JF Holland |
| |
JCO May 1 1996: 1589–1598.
[Abstract]
[PDF]
|
|
|
Radioimmunoguided surgery after primary treatment of locally advanced breast cancer |
| |
P Percivale, S Bertoglio, P Meszaros, G Canavese, F Cafiero, M Gipponi, E Campora, M Gasco, and F Badellino |
| |
JCO May 1 1996: 1599–1603.
[Abstract]
[PDF]
|
|
|
p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients |
| |
R Silvestrini, E Benini, S Veneroni, MG Daidone, G Tomasic, P Squicciarini, and B Salvadori |
| |
JCO May 1 1996: 1604–1610.
[Abstract]
[PDF]
|
|
|
Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: a phase II trial |
| |
JD Hainsworth, SE Jones, RG Mennel, JL Blum, and FA Greco |
| |
JCO May 1 1996: 1611–1616.
[Abstract]
[PDF]
|
|
|
Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony- stimulating factor for the treatment of hormone-resistant prostate cancer |
| |
EJ Small, S Srinivas, B Egan, A McMillan, and TP Rearden |
| |
JCO May 1 1996: 1617–1625.
[Abstract]
[PDF]
|
|
|
Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy |
| |
PJ Rosen, EF Mendoza, EM Landaw, B Mondino, MC Graves, JH McBride, P Turcillo, J deKernion, and A Belldegrun |
| |
JCO May 1 1996: 1626–1636.
[Abstract]
[PDF]
|
|
|
Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients |
| |
AW Stephens, R Gonin, GD Hutchins, and LH Einhorn |
| |
JCO May 1 1996: 1637–1641.
[Abstract]
[PDF]
|
|
|
Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer |
| |
FA Greco, SL Stroup, JR Gray, and JD Hainsworth |
| |
JCO May 1 1996: 1642–1648.
[Abstract]
[PDF]
|
|
|
Phase II trial of docetaxel in previously untreated advanced non-small- cell lung cancer: a Japanese cooperative study |
| |
H Kunitoh, K Watanabe, T Onoshi, K Furuse, H Niitani, and T Taguchi |
| |
JCO May 1 1996: 1649–1655.
[Abstract]
[PDF]
|
|
|
Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose |
| |
FA Shepherd, R Burkes, Y Cormier, M Crump, R Feld, T Strack, and M Schulz |
| |
JCO May 1 1996: 1656–1662.
[Abstract]
[PDF]
|
|
|
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer |
| |
EE Vokes, R Mick, MS Kies, ME Dolan, D Malone, I Athanasiadis, DJ Haraf, M Kozloff, RR Weichselbaum, and MJ Ratain |
| |
JCO May 1 1996: 1663–1671.
[Abstract]
[PDF]
|
|
|
Docetaxel: an active drug for squamous cell carcinoma of the head and neck |
| |
AI Dreyfuss, JR Clark, CM Norris, RM Rossi, JW Lucarini, PM Busse, MD Poulin, L Thornhill, R Costello, and MR Posner |
| |
JCO May 1 1996: 1672–1678.
[Abstract]
[PDF]
|
|
|
Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities |
| |
PW Pisters, DH Leung, J Woodruff, W Shi, and MF Brennan |
| |
JCO May 1 1996: 1679–1689.
[Abstract]
[PDF]
|
|
|
The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy |
| |
M Hernberg, T Muhonen, JP Turunen, M Hahka-Kemppinen, and S Pyrhonen |
| |
JCO May 1 1996: 1690–1696.
[Abstract]
[PDF]
|
|
|
Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study |
| |
E Tartour, JY Blay, T Dorval, B Escudier, V Mosseri, JY Douillard, L Deneux, I Gorin, S Negrier, C Mathiot, P Pouillart, and WH Fridman |
| |
JCO May 1 1996: 1697–1703.
[Abstract]
[PDF]
|
|
|
Needle aspiration techniques in preoperative selection of patients with thyroid nodules: a long-term study |
| |
A Carpi, E Ferrari, MG Toni, A Sagripanti, A Nicolini, and G Di Coscio |
| |
JCO May 1 1996: 1704–1712.
[Abstract]
[PDF]
|
|
|
A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials Group |
| |
E Bruera, P Sloan, B Mount, J Scott, and M Suarez-Almazor |
| |
JCO May 1 1996: 1713–1717.
[Abstract]
[PDF]
|
|
|
Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer |
| |
J Bines, DM Oleske, and MA Cobleigh |
| |
JCO May 1 1996: 1718–1729.
[Abstract]
[PDF]
|
|
|
Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996 |
| |
|
| |
JCO May 1 1996: 1730–1736.
[Abstract]
[PDF]
|
|
| Carboplatin and cisplatin in medulloblastoma at diagnosis: "comparable efficacy?" |
| R Mastrangelo, A Lasorella, A Tornesello, and R Riccardi |
|
JCO May 1 1996: 1741a.
[PDF]
|
|
| Role of granulocyte-macrophage colony-stimulating factor in chemotherapy-induced oral mucositis |
| AM Wardley and JH Scarffe |
|
JCO May 1 1996: 1741b–1743.
[PDF]
|
|
| Maculopapular rashes secondary to gemcitabine injection for non-small- cell lung cancer |
| YM Chen, JM Liu, CM Tsai, J Whang-Peng, and RP Perng |
|
JCO May 1 1996: 1743–1744.
[PDF]
|
|
